GOLD. Global Strategy for the Diagnosis, Management and Prevention of COPD. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Updated 2016. Available from http://www.goldcopd.org/http://www.goldcopd.org/

Hogg JC, McDonough JE, Suzuki M. Small airway obstruction in COPD: new insights based on micro-CT imaging and MRI imaging. Chest, 2013, 143: 1436-43.

Decramer M, Janssens W, Miravitlles M. Chronic obstructive pulmonary disease. Lancet, 2012, 379: 1341-51.

Chuchalin AG, Khaltaev N, Antonov NS, et al. Chronic respiratory diseases and risk factors in 12 regions of the Russian Federation. Int J COPD, 2014, 9: 963-974.

Hoyert DL, Xu J. Deaths: preliminary data for 2011. Natl Vital Stat Rep, 2012, 61: 1-51.

Mannino DM, Homa DM, Akinbami LJ, Ford ES, Redd SC. Chronic Obstructive Pulmonary Disease Surveillance – United States, 1971–2000. MMWR Surveillance Summaries, 2002, 51(SS06): 1-16.

Rodrigo GJ, Plaza V. Efficacy and safety of a fixeddose combination of indacaterol and Glycopyrronium (QVA149) for the treatment of COPD: a systematic review. Chest, 2014, 146: 309-317.

Ball DI, Brittain RT, Coleman RA, Denyer LH, Jack D, Johnson M, Lunts LH, Nials AT, Sheldrick KE, Skidmore IF. Salmeterol, a novel, long-acting beta 2-adrenoceptor agonist: characterization of pharmacological activity in vitro and in vivo. Br J Pharmacol, 1991, 104: 665-71.

Casarosa P, Bouyssou T, Germeyer S, Schnapp A, Gantner F, Pieper M. Preclinical evaluation of long-acting muscarinic antagonists: comparison of tiotropium and investigational drugs. J Pharmacol Exp Ther, 2009, 330: 660-8.

Borrill ZL, Houghton CM, Woodcoc k AA, Vestbo J, Singh D . Measuring bronchodilation in COPD clinical trials. Br J Clin Pharmacol, 2005, 59: 379-84.

Renard D, Looby M, Kramer B, Lawrence D, Morris D, Stanski DR. Characterization of the bronchodilatory dose response to indacaterol in patients with chronic obstructive pulmonary disease using model-based approaches. Respir Res, 2011, 12: 54.

Rennard S, Bantje T, Centanni S, Chanez P, Chuchalin A, D’Urzo A, Kornmann O, Perry S, Jack D, Owen R, Higgins M. A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison. Respir Med, 2008, 102: 1033-44.

Singh D, Magnussen H, Kirsten A, Mindt S, Caracta C, Seoane B, Jarreta D, Garcia Gil E. A randomised, placebo- and active-controlled dose-finding study of aclidinium bromide administered twice a day in COPD patients. Pulm Pharmacol Ther, 2012, 25: 248-53.

Cazzola M, Page CP, Calzetta L, Matera MG. Pharmacology and therapeutics of bronchodilators. Pharmacol Rev, 2012, 64: 450-504.

Hanania NA, Boota A, Kerwin E, Tomlinson L, Denis-Mize K. Efficacy and safety of nebulized formoterol as add-on therapy in COPD patients receiving maintenance tiotropium bromide: Results from a 6-week, randomized, placebo-controlled, clinical trial. Drugs, 2009, 69: 1205-16.

Tashkin DP, Littner M, Andrews CP, Tomlinson L, Rinehart M, Denis-Mize K. Concomitant treatment with nebulized formoterol and tiotropium in subjects with COPD: a placebo-controlled trial. Respir Med, 2008, 102: 479-87.

Tashkin DP, Pearle J, Iezzoni D, Varghese ST. Formoterol and tiotropium compared with tiotropium alone for treatment of COPD. COPD, 2009, 6: 17-25.

Terzano C, Petroianni A, Conti V, Ceccarelli D, Graziani E, Sanduzzi A, D’Avelli S. Rational timing of combination therapy with tiotropium and formoterol in moderate and severe COPD. Respir Med, 2008, 102: 1701-7.

van Noord JA, Aumann JL, Janssens E, Verhaert J, Smeets JJ, Mueller A, Cornelissen PJ. Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest, 2006, 129: 509-17.

Mahler D, D’Urzo A, Peckitt C, Lassen C, Kramer B, Filcek S. Combining once-daily bronchodilators in COPD: indacaterol plus tiotropium versus tiotropium alone. Am J Respir Crit Care Med, 2011, 183: A1591.

Aaron SD, Vandemheen KL, Fergusson D, Maltais F, Bourbeau J, Goldstein R et al, Canadian Thoracic Society/Canadian Respiratory Clinical Research C. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med, 2007, 146: 545-55.

Tashkin DP, Donohue JF, Mahler DA, Huang H, Goodwin E, Schaefer K, Hanrahan JP, Andrews WT. Effects of arformoterol twice daily, tiotropium once daily, and their combination in patients with COPD. Respir Med, 2009, 103: 516-24.

van Noord JA, Aumann JL, Janssens E, Smeets JJ, Verhaert J, Disse B, Mueller A, Cornelissen PJ. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J, 2005, 26: 214-22.

van Noord JA, Aumann JL, Janssens E, Smeets JJ, Zaagsma J, Mueller A, Cornelissen PJ. Combining tiotropium and salmeterol in COPD: Effects on airflow obstruction and symptoms. Respir Med, 2010, 104: 995-1004.

Vogelmeier C, Kardos P, Harari S, Gans SJ, Stenglein S, Thirlwell J. Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month study. Respir Med, 2008, 102: 1511-20.

van Noord JA, Buhl R, Laforce C, Martin C, Jones F, Dolker M, Overend T. ИНД/ГЛИ demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease. Thorax, 2010, 65: 1086-91.

Calverley PM, Burge PS, Spencer S, Anderson JA, Jones PW. Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax, 2003, 58: 659-64.

Cazzola M, Segreti A, Matera MG. New developments in the combination treatment of COPD: focus on umeclidinium/vilanterol. Drug Des Devel Ther, 2013, 7: 1201-8.

Dahl R, Chapman KR, Rudolf M, Mehta R, Kho P, Alagappan VK, Chen H, Banerji D. Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN study. Respir Med, 2013, 107: 1558-1567.

Bateman ED, Ferguson GT, Barnes N, Gallagher N, Green Y, Henley M, Banerji D. Dual bronchodilation with QVA149versus single bronchodilator therapy: the SHINE study. Eur Respir J, 2013, 42: 1484-1494.

Wedzicha JA, Decramer M, Ficker JH, Niewoehner DE, Sandstrom T, Fowler Taylor A, D’Andrea P, Arrasate C, Chen H, Banerji D. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir Med, 2013, 1: 199-209.

Banerji D, Fedele MJ, Chen H, Kim HJ. Dual bronchodilation with QVA149reduces COPD exacerbations: results from the ignite program. Respirology, 2013, 18(Suppl 4): 1-81.

Vogelmeier CF, Bateman ED, Pallante J, Alagappan VK, D’Andrea P, Chen H, Banerji D. Efficacy and safety of once-daily QVA149compared with twicedaily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel-group study. Lancet Respir Med, 2013, 1: 51-60.

Zhong N, Wang C, Zhou X, Zhang N, Humphries M, Wang C, Thach C, Patalano F, Banerji D. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD. Int J COPD, 2015, 10: 1015-26.

Beeh K-M, Korn S, Beier J, Jadayel D, Henley M, D’Andrea P, Banerji D. Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: the BRIGHT study. Respir Med, 2014, 108: 584-592.

Mahler DA, Decramer M, D’Urzo A, Worth H, White T, Alagappan VK, Chen H, Gallagher N, Kulich K, Banerji D. Dual bronchodilation with QVA149reduces patient-re ported dyspnoea in COPD: the BLAZE study. Eur Respir J, 2014, 43: 1599-1609.

Wedzicha JA, Banerji D, Chapman KR, Vestbo J, Roche N, Ayers RT, Thach C, Fogel R, Patalano F, Vogelmeier C. Indacaterol-g lycopyrronium versus salmeterol-fluticasone for COPD. N Engl J Med, 2016, 374: 2222-34.

Dahl R, Gallagher N, Green Y, Bryant H, Chen H, D’Andrea P, Alagappan V, Banerji D. QVA149 provides a rapid onset of action which is sustained throughout treatment in patients with COPD. Eur Respir J, 2013, 42(Suppl 57): 3385.

Dahl R, Jadayel D, Alagappan VK, Chen H, Banerji D. Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON study. Int J COPD, 2013, 8: 501-508.

Ferguson G, Barnes N, Mehta R. Cardio- and cerebro-vascular safety profile of QVA149 in patients with COPD: a pooled analysis [Abstract]. Am J Respir Crit Care Med, 2013, 187(1): A1488.

Wedzicha JA, Dahl R, Buhl R, Schubert-Tennigkeit A, Chen H, D’Andrea P, Fogel R, Banerji D. Pooled safety analysis of the fixed-dose combination of indacaterol and glycopyrronium (QVA149), its monocomponents, and tiotropium versus placebo in COPD patients. Respir Med, 2014, 108: 1498-1507.

Pavkov R, Mueller S, Fiebich K, Singh D, Stowasser F, Pignatelli G, Walter B, Ziegler D, Dalvi M, Dederichs J, Rietveld I. Characteristics of a capsule based dry powder inhaler for the delivery of indacaterol. Curr Med Res Opin, 2010, 26: 2527-2533.

Restrepo RD, Alvarez MT, Wittnebel LD, Sorenson H, Wettstein R, Vines DL, Sikkerna-Ortiz J, Gardner DD, Wilkins RL. Medication adherence issues in patients treated for COPD. Int J COPD, 2008, 3: 371-384.